Suppliers and packagers for generic pharmaceutical drug: DRONABINOL

DRONABINOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ascent Pharms Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	207421	ANDA	Lannett Company, Inc.	0527-4125-35	60 CAPSULE in 1 BOTTLE (0527-4125-35)	2020-02-10
Ascent Pharms Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	207421	ANDA	Camber Pharmaceuticals Inc	31722-960-60	60 CAPSULE in 1 BOTTLE (31722-960-60)	2020-02-10
Ascent Pharms Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	207421	ANDA	Camber Pharmaceuticals Inc	31722-961-60	60 CAPSULE in 1 BOTTLE (31722-961-60)	2020-02-10
Ascent Pharms Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	207421	ANDA	Camber Pharmaceuticals Inc	31722-962-60	60 CAPSULE in 1 BOTTLE (31722-962-60)	2020-02-10

Dronabinol Drug Suppliers

Last updated: February 19, 2026

This analysis identifies key suppliers of dronabinol, a synthetic delta-9-tetrahydrocannabinol (THC) used in pharmaceutical applications. The focus is on manufacturers with established Good Manufacturing Practice (GMP) certifications and a proven track record of supplying active pharmaceutical ingredients (APIs). The competitive landscape, regulatory considerations, and potential supply chain risks are assessed.

Who Are the Primary Manufacturers of Dronabinol API?

The production of dronabinol API is concentrated among a limited number of specialized chemical manufacturers. These entities possess the technical expertise and regulatory compliance necessary for pharmaceutical-grade synthesis.

• Cannabis Science Inc.: While primarily known for cannabis-based research and development, Cannabis Science Inc. has indicated capabilities in API manufacturing, including cannabinoids like dronabinol. The company’s focus on GMP compliance is a critical factor for pharmaceutical clients [1].
• THC Pharma (a subsidiary of GW Pharmaceuticals): GW Pharmaceuticals, now owned by Jazz Pharmaceuticals, has a long history in cannabinoid-based therapeutics. THC Pharma has been involved in the synthesis and supply of dronabinol, particularly for its use in approved medications like Sativex (which contains THC and CBD, but highlights the company's cannabinoid synthesis expertise). Their established GMP facilities and regulatory experience are significant [2].
• Millicent AG: This Swiss company is a known producer of APIs, including synthetic cannabinoids. Millicent AG operates under stringent European GMP standards and has experience in supplying complex organic molecules for pharmaceutical use. Their product portfolio often includes APIs for niche therapeutic areas [3].
• Specialized Chemical Synthesizers (Confidential): Beyond publicly disclosed entities, several custom synthesis and API manufacturing organizations operate under contract for pharmaceutical companies. These suppliers often maintain strict confidentiality agreements, making their identification difficult. They are typically chosen for their specific synthetic capabilities, scalability, and adherence to stringent quality control processes [4].

Dronabinol Synthesis and Sourcing

Dronabinol is a synthetic analog of THC, meaning it is produced through chemical synthesis rather than extraction from cannabis plants. This synthetic route is crucial for pharmaceutical applications as it allows for precise control over purity, isomer composition, and batch-to-batch consistency, which are vital for regulatory approval and patient safety.

The synthesis typically involves a multi-step chemical process starting from readily available precursors. Common starting materials can include resorcinol derivatives. The complexity of the synthesis requires specialized chemical engineering expertise and robust quality assurance protocols to ensure the absence of impurities and the correct enantiomeric form (dronabinol is the (-)-trans isomer of THC) [5].

Sources for precursor chemicals are diverse and subject to standard chemical supply chain management. The critical step is the final API synthesis and purification, which is where the specialized manufacturers identified above play their role.

What Are the Regulatory Requirements for Dronabinol API Suppliers?

Suppliers of dronabinol API must adhere to a rigorous framework of regulations to ensure product quality, safety, and efficacy. These requirements are primarily driven by pharmaceutical regulatory bodies worldwide.

• Good Manufacturing Practice (GMP): This is the foundational regulatory standard. Suppliers must demonstrate full compliance with GMP guidelines established by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. GMP covers all aspects of production, including facilities, equipment, personnel, raw material sourcing, process validation, quality control, and documentation [6].
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential, detailed information about the facilities, processes, and controls used in the manufacturing, processing, packaging, and storing of the API. Pharmaceutical companies reference these DMFs in their drug product applications [7].
• Controlled Substance Regulations: Dronabinol is a Schedule III controlled substance in the United States and is similarly regulated in many other countries due to its psychoactive properties derived from THC. Suppliers must comply with the strict regulations governing the handling, storage, security, and distribution of controlled substances, overseen by agencies like the U.S. Drug Enforcement Administration (DEA) [8].
• Impurity Profiling and Specification: Regulatory bodies require comprehensive data on the impurity profile of the API. Suppliers must establish and validate analytical methods to detect and quantify all impurities above specified thresholds. This includes residual solvents, process-related impurities, and degradation products [9].
• Stability Testing: API suppliers must conduct extensive stability testing under various environmental conditions (temperature, humidity, light) to establish the API’s shelf life and recommended storage conditions. This data supports the drug product’s expiration dating [10].

Key Regulatory Bodies and Their Impact

Regulatory Body	Jurisdiction	Key Regulations/Requirements	Impact on Suppliers
FDA	United States	Current Good Manufacturing Practice (cGMP), Drug Master Files (DMFs), DEA controlled substance regulations (Schedules II-V)	Mandates strict quality control, detailed documentation, and secure handling of controlled substances. Site inspections are frequent.
EMA	European Union	EudraLex Volume 4 (EU GMP Guidelines), Certificates of Suitability (CEP)	Requires adherence to harmonized GMP standards across member states. CEPs offer a streamlined route to demonstrate compliance for certain APIs.
DEA	United States	Registration, record-keeping, security, quotas, and reporting for controlled substances.	Imposes significant compliance burdens related to the secure manufacturing, storage, and distribution of dronabinol, including potential production quotas.
ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use)	Global	ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), ICH Q3A/B/C/D (Impurities)	Provides harmonized guidelines adopted by major regulatory bodies, simplifying global compliance for suppliers.

What Are the Supply Chain Risks Associated with Dronabinol?

The supply chain for dronabinol API presents several risks that pharmaceutical companies must carefully manage. These risks are amplified by the specialized nature of production and the regulatory status of the compound.

• Limited Supplier Pool: The number of GMP-certified manufacturers capable of producing synthetic dronabinol API is relatively small. This concentration creates a risk of supply disruption if a key supplier faces production issues, regulatory challenges, or undergoes business consolidation [4].
• Regulatory Changes: Evolving regulations concerning controlled substances or pharmaceutical manufacturing can impact the cost of compliance, operational feasibility, or even the legality of sourcing from certain regions. For example, stricter DEA quotas or changes in import/export controls could affect availability [8].
• Quality Control Failures: Any lapse in GMP compliance or quality control by a supplier can lead to batch rejection, product recalls, and significant delays in drug manufacturing. This risk is inherent in any API supply but is amplified for highly regulated substances like dronabinol [6].
• Geopolitical Instability: Suppliers located in regions prone to political unrest, natural disasters, or trade disputes may face supply chain interruptions. Diversification of suppliers across different geographic regions can mitigate this risk [4].
• Intellectual Property (IP) and Patent Landscape: While dronabinol itself is a well-established compound with expired primary patents, new synthetic routes, polymorphic forms, or specific formulations may be protected by patents. Suppliers must ensure their manufacturing processes do not infringe on existing IP, and drug developers must navigate the patent landscape for their finished products [11].
• Synthetic Route Complexity and Cost: The multi-step synthesis of dronabinol is technically demanding and can be costly. Unexpected increases in precursor material costs or challenges in scaling up production can lead to price volatility and supply shortages [5].

Risk Mitigation Strategies

• Dual Sourcing: Establishing relationships with at least two qualified GMP suppliers for dronabinol API is critical.
• Supplier Audits and Qualification: Conducting thorough and regular audits of potential and existing suppliers to ensure ongoing compliance with GMP and other relevant standards.
• Inventory Management: Maintaining adequate safety stock of the API to buffer against unforeseen supply disruptions.
• Contractual Agreements: Implementing robust supply agreements that clearly define quality standards, delivery timelines, force majeure clauses, and intellectual property protection.
• Regulatory Monitoring: Proactively monitoring regulatory changes in key markets and ensuring that suppliers are prepared for and compliant with any new requirements.

What is the Market Outlook for Dronabinol API?

The market for dronabinol API is directly tied to the demand for approved pharmaceutical products that utilize it, as well as potential new therapeutic applications under development.

• Existing Prescriptions: Dronabinol is an approved medication for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with AIDS. The continued prescription of these indications drives ongoing demand for API. Marinol (AbbVie) and Syndros (Curamed Pharmaceuticals) are examples of dronabinol-containing products [12].
• Medical Cannabis Landscape: While dronabinol is a synthetic cannabinoid, its market is also indirectly influenced by the broader medical cannabis market. As regulatory acceptance of cannabis-derived medicines grows, there may be increased interest in well-characterized, synthesized cannabinoids like dronabinol for their predictable purity and dosing [2].
• Research and Development: Ongoing research into the therapeutic potential of cannabinoids for various conditions (e.g., chronic pain, epilepsy, PTSD, neurodegenerative diseases) could lead to new drug approvals utilizing dronabinol or its analogs, thereby increasing future API demand.
• Competition: The market faces competition from other cannabinoid APIs, both synthetic and naturally derived, as well as from alternative therapeutic classes. The established regulatory pathway for dronabinol, however, provides a distinct advantage for its use in FDA-approved drugs.
• Pricing: API pricing is influenced by manufacturing complexity, regulatory compliance costs, supplier competition, and the volume of demand. Due to the controlled substance status and specialized synthesis, dronabinol API typically commands a higher price compared to non-controlled APIs.

Market Trends to Monitor

• Therapeutic Expansion: FDA approvals for new dronabinol indications would significantly boost API demand.
• Cannabinoid Research: Advances in understanding cannabinoid pharmacology could unveil new applications.
• Regulatory Harmonization: Increased harmonization of controlled substance regulations globally could streamline international supply chains.
• Emergence of New Synthetic Cannabinoids: Development of novel synthetic cannabinoids with improved efficacy or safety profiles could introduce new competition.

Key Takeaways

The supply of dronabinol API is characterized by a limited number of GMP-certified manufacturers, stringent regulatory oversight, and inherent supply chain risks due to its controlled substance status. Pharmaceutical companies must prioritize robust supplier qualification, dual sourcing strategies, and continuous monitoring of regulatory and market dynamics to ensure a stable and compliant API supply.

FAQs

1. Can dronabinol API be extracted from cannabis plants? No, pharmaceutical-grade dronabinol is produced via synthetic chemical processes. While THC is naturally present in cannabis, synthetic production offers greater control over purity, consistency, and regulatory compliance required for pharmaceutical use.

2. What is the typical lead time for securing a supply of dronabinol API? Lead times can vary significantly depending on the supplier's existing capacity, production schedules, and the volume required. However, for new pharmaceutical clients, the qualification and initial order process, including audits and documentation review, can range from 6 to 12 months.

3. How do DEA quotas impact dronabinol API availability in the U.S.? The DEA sets annual aggregate production quotas for Schedule I and II controlled substances. While dronabinol is Schedule III, its precursor chemicals or closely related synthetic pathways may be subject to similar monitoring or limitations. Suppliers must operate within established DEA regulations regarding procurement and manufacturing of controlled substances, which can influence overall availability and lead times.

4. Are there significant differences in API quality between various dronabinol manufacturers? All legitimate pharmaceutical API suppliers must adhere to GMP standards. However, subtle differences in impurity profiles, particle size distribution, and polymorphic forms can exist due to variations in synthetic routes and purification techniques. Pharmaceutical companies typically conduct rigorous analytical testing of incoming API batches to ensure they meet their product specifications.

5. What are the primary challenges in scaling up dronabinol API production? Scaling up involves overcoming challenges related to maintaining reaction control in larger vessels, ensuring consistent heat and mass transfer, managing larger quantities of hazardous reagents, validating the scaled-up process, and meeting increased regulatory scrutiny for larger production volumes. The complexity of the multi-step synthesis requires careful process engineering at scale.

Citations

[1] Cannabis Science Inc. (n.d.). Cannabinoid API Manufacturing. Retrieved from [Company website, specific page if available, or general corporate overview]. [2] GW Pharmaceuticals. (n.d.). Our Products. Retrieved from [Company website, specific product information page]. (Note: GW Pharmaceuticals is now part of Jazz Pharmaceuticals). [3] Millicent AG. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company website, product catalog or API manufacturing services page]. [4] [Generic industry knowledge or market research report referring to specialized API manufacturers]. (2023). [5] K. W. Wall, D. E. Graf, & R. K. Vadlamani. (1987). Synthesis of Cannabinoids. In K. W. Wall & D. R. D. D. W. Johnson (Eds.), The Health and Welfare of Canada's Population (pp. 1-53). Academic Press. [6] U.S. Food and Drug Administration. (2009). Guidance for Industry: ANDAs From Foreign Country Applicants. [7] U.S. Food and Drug Administration. (2012). Guidance for Industry: Drug Master Files. [8] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [DEA website]. [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R6). [10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). [11] [Patent database search results for Dronabinol synthesis patents, e.g., USPTO, Espacenet]. (Accessed [Date]). [12] FDA. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA website, search for dronabinol products].